Product Images Terazosin

The text describes data from Study 1, presented in Figure 1. The graph shows the mean change in the total symptom score and mean increase in peak flow rate from baseline for patients taking Terazosin or a placebo over a period of three months. The table above the graph provides the baseline values for the patients. The results indicate that Terazosin is more effective than the placebo in reducing total symptom score and increasing peak flow rate, with statistical significance indicated.*

The text describes a figure labeled as Figure 2 showing the mean change in total symptom score from baseline in a long-term, open-label, non-placebo controlled study with 194 participants. The graph indicates that there was a significant improvement in symptoms over a period of 30 weeks, with a mean change from baseline of approximately 4%. There is also a note indicating that the difference was statistically significant (p <005) when compared to baseline, and that the mean baseline score was 10.7.*

This is a figure from a long-term, open-label, non-placebo controlled study showing the mean change in peak flow rate from baseline. The figure includes data points at different time points (0, 1, 2, 3, 6, 12, 15, 16, 21, 24, 27, and 30 months) and indicates that there was a statistically significant improvement in peak flow rate compared to baseline (p<0.05). The mean baseline peak flow rate was 9.9.*

These are Terazosin Capsules of strengths 10mg, packaged in a bottle containing 30 capsules. It is a prescription medicine and should be stored at room temperature. The Lot# is BPO000000D and it was packaged by Blanhaim Pharmacal Inc. The text also provides information about the manufacturer, dosage and warnings about keeping it out of reach of children. There are also details about the equivalent of Fefazosi Hydrochloride in the capsules; however, there are some typos and inconsistent spellings in the text.*